SITC与INMC联合更新泛肿瘤新辅助治疗病理缓解评分指南
该指南由病理学、肿瘤学与外科领域专家共同制定,基于与患者结局相关的组织学特征,更新并标准化新辅助治疗后病理缓解的评估与报告体系。推荐肿瘤≤3 cm时全部取材行组织学分析,通过残余活肿瘤百分比、坏死与退缩量化病理缓解,并提供标准化报告模板。标准化有助于将病理缓解作为长期结局的替代终点并支持适应性辅助治疗决策。
要点
- 推荐肿瘤≤3 cm时全部取材行组织学分析
- 通过残余活肿瘤百分比、坏死与退缩量化病理缓解
- 提供标准化报告模板并建议收集额外关键数据点
核心结论
- 标准化泛肿瘤病理缓解评分有助于一致可靠地分层患者结局并支持临床试验间比较。
研究设计与样本
- 由病理学、肿瘤学与外科领域专家(含SITC PATHdata与INMC代表)召开会议制定更新版共识指南。
主要发现
- 推荐肿瘤≤3 cm时全部取材行组织学分析,并对较大肿瘤提供额外取材指导。
- 病理缓解通过残余活肿瘤百分比、坏死与退缩进行量化评估。
- 提供需评分组织学特征的描述及标准化报告模板。
- 建议收集额外关键数据点以支持该泛肿瘤方法的持续验证。
关键数值与推荐
- 肿瘤≤3 cm时推荐全部取材行组织学分析。
- 病理缓解量化指标包括残余活肿瘤百分比、坏死与退缩。
临床怎么用
- 在常规临床中按标准化模板评估并报告新辅助治疗后病理缓解,以支持适应性辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Practice-changing clinical trials for novel therapeutic regimens administered in the neoadjuvant setting have been reported for multiple cancer types, bringing this treatment strategy to the forefront for patients with high-risk surgically resectable disease. Previously, tumor-type- or therapy-type-specific scoring systems were used for pathologic response assessment. The goal of this effort is to update, harmonize, and standardize the emerging system(s) for pathologic response assessment and data capture. MATERIALS AND METHODS: Leaders in pathology, oncology, and surgery, including those from the Society for Immunotherapy of Cancer's Pan-tumor Harmonization of Pathologic Response Assessment (PATHdata) efforts and the International Neoadjuvant Melanoma Consortium (INMC), convened to develop updated consensus guidelines for pathologic response assessment, including specimen handling and tissue submission, scoring, and reporting. This paper builds upon previous recommendations, which are updated based on histologic features associated with patient outcomes. Specific attention was paid to commonalities across tumor types, as well as tumor-type-specific considerations. RESULTS: A revised and standardized approach to tissue submission is recommended, including total submission of tumors ≤3 cm in size for histologic analysis. Additional guidance is provided for larger tumors. Pathologic response is quantified through assessments of percentage of residual viable tumor (%RVT), necrosis, and regression. Descriptions of histologic features to be scored are provided together with a standardized reporting template. Recommendations regarding collecting additional key datapoints are also made, to allow continued, extended validation of this pan-tumor approach. CONCLUSIONS: As pathologic response emerges as a surrogate endpoint for long-term clinical outcomes and to help inform adaptive adjuvant therapy decisions in routine clinical care, standardization is critical to facilitate consistent and reliable application. This pan-tumor approach to scoring and reporting supports robust stratification of patient outcomes, facilitates comparisons across clinical trials and tumor types, enhances data collection, and establishes a foundation for identifying additional, clinically meaningful %RVT cut points.
引用
- Deutsch JS, Scolyer RA, Burton E, et al. Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort. Ann Oncol. 2025. PMID: 41469296. doi:10.1016/j.annonc.2025.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。